|Systematic (IUPAC) name|
|1-(2-methylbenzoxazol- 6-yl)- 3-[1,5]naphthyridin- 4-yl urea|
|Mol. mass||319.317 g/mol|
SB-334867 is an orexin antagonist. It was the first non-peptide antagonist developed that is selective for the orexin receptor subtype OX1, with around 50x selectivity for OX1 over OX2 receptors. It has been shown to produce sedative and anorectic effects in animals, and has been useful in characterising the orexinergic regulation of brain systems involved with appetite and sleep, as well as other physiological processes. Orexin antagonists have multiple potential clinical applications including the treatment of drug addiction, insomnia, obesity and diabetes.
- Smart, D; Sabido-David, C; Brough, SJ; Jewitt, F; Johns, A; Porter, RA; Jerman, JC (2001). "SB-334867-A: the first selective orexin-1 receptor antagonist".
- Rodgers, RJ; Halford, JC; Nunes De Souza, RL; Canto De Souza, AL; Piper, DC; Arch, JR; Upton, N; Porter, RA; Johns, A (2001). "SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats". The European Journal of Neuroscience 13 (7): 1444–52.
- Haynes, AC; Chapman, H; Taylor, C; Moore, GB; Cawthorne, MA; Tadayyon, M; Clapham, JC; Arch, JR (2002). "Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice". Regulatory peptides 104 (1–3): 153–9.
- Rodgers, RJ; Ishii, Y; Halford, JC; Blundell, JE (2002). "Orexins and appetite regulation". Neuropeptides 36 (5): 303–25.
- Bernard, R; Lydic, R; Baghdoyan, HA (2003). "Hypocretin-1 causes G protein activation and increases ACh release in rat pons". The European Journal of Neuroscience 18 (7): 1775–85.
- Soffin, EM; Gill, CH; Brough, SJ; Jerman, JC; Davies, CH (2004). "Pharmacological characterisation of the orexin receptor subtype mediating postsynaptic excitation in the rat dorsal raphe nucleus". Neuropharmacology 46 (8): 1168–76.
- Thorpe, AJ; Kotz, CM (2005). "Orexin a in the nucleus accumbens stimulates feeding and locomotor activity". Brain Research 1050 (1–2): 156–62.
- Frederick-Duus, D; Guyton, MF; Fadel, J (2007). "Food-elicited increases in cortical acetylcholine release require orexin transmission". Neuroscience 149 (3): 499–507.
- Small, CJ; Goubillon, ML; Murray, JF; Siddiqui, A; Grimshaw, SE; Young, H; Sivanesan, V; Kalamatianos, T; Kennedy, AR (2003). "Central orexin a has site-specific effects on luteinizing hormone release in female rats". Endocrinology 144 (7): 3225–36.
- D'anna, KL; Gammie, SC (2006). "Hypocretin-1 dose-dependently modulates maternal behaviour in mice". Journal of neuroendocrinology 18 (8): 553–66.
- Muschamp, JW; Dominguez, JM; Sato, SM; Shen, RY; Hull, EM (2007). "A role for hypocretin (orexin) in male sexual behavior". Journal of Neuroscience 27 (11): 2837–45.
- Eliassi, A; Nazari, M; Naghdi, N (2009). "Role of the ventromedial hypothalamic orexin-1 receptors in regulation of gastric Acid secretion in conscious rats". Journal of neuroendocrinology 21 (3): 177–82.
- Smart, D; Haynes, AC; Williams, G; Arch, JR (2002). "Orexins and the treatment of obesity". European Journal of Pharmacology 440 (2–3): 199–212.
- Bingham, MJ; Cai, J; Deehan, MR (2006). "Eating, sleeping and rewarding: orexin receptors and their antagonists". Current opinion in drug discovery & development 9 (5): 551–9.
- Borgland, SL; Taha, SA; Sarti, F; Fields, HL; Bonci, A (2006). "Orexin a in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine". Neuron 49 (4): 589–601.
- Narita, M; Nagumo, Y; Hashimoto, S; Narita, M; Khotib, J; Miyatake, M; Sakurai, T; Yanagisawa, M; Nakamachi, T (2006). "Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine". Journal of Neuroscience 26 (2): 398–405.
- Lawrence, AJ; Cowen, MS; Yang, HJ; Chen, F; Oldfield, B (2006). "The orexin system regulates alcohol-seeking in rats". British Journal of Pharmacology 148 (6): 752–9.
- Sharf, R; Sarhan, M; Dileone, RJ (2008). "Orexin Mediates the Expression of Precipitated Morphine Withdrawal and Concurrent Activation of the Nucleus Accumbens Shell". Biological Psychiatry 64 (3): 175–83.
- Aston-Jones, G; Smith, RJ; Moorman, DE; Richardson, KA (2009). "Role of lateral hypothalamic orexin neurons in reward processing and addiction". Neuropharmacology. 56 Suppl 1 (Suppl 1): 112–21.
- Martin-Fardon, R; et al (2014). "Blockade of hypocretin receptor-1 preferentially prevents cocaine seeking: comparison with natural reward seeking". NeuroReport.